Settlement Mechanics and Opt-Out Dynamics
The $275 million fund may be reduced by up to $45 million to account for opt-outs. According to filings, only one consumer requested to opt out, but over 50 entities filed exclusions, including municipalities, businesses, and insurers.
Class counsel has requested up to one-third of the fund ($67.7M–$82.7M) in attorneys’ fees, plus $26 million for expenses and $500,000 for service awards. An additional $750,000 is allocated for administrative costs. The remaining funds would be distributed pro rata based on drug purchase data from class members.
Parallel Settlements and Trials Ahead
Sandoz previously paid $265 million to settle with pharmacies and direct purchasers. The company, spun off from Novartis AG, has denied wrongdoing but says these settlements reflect a break from legacy practices.
Meanwhile, the broader MDL continues, with the first jury trials scheduled for August. Separate state actions in Connecticut and a DOJ prosecution of Teva Pharmaceuticals further complicate the sprawling litigation landscape.
